Insider · CIK 0001417976
Andrew H Galligan
Files at OOMA (OOMA INC), ACLX (Arcellx, Inc.). First filing Dec 19, 2024, latest Jun 24, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OOMA: OOMA INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | OOMA INC | $154k 12,407 shares | -5% | +14% from low-22% from high | |
| 27Weak | OOMA INC | $216k 14,824 shares | -6% | +33% from low-8% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 23, 2025 | OOMA OOMA INC | SOpen-market sale Common Stock | -12,407 | $12.43 | $154k | 241,081 | Jun 24, 2025 |
| Jun 5, 2025 | OOMA OOMA INC | AGrant or award Common Stock | +11,556 | $0.00 | $0 | 253,488 | Jun 9, 2025 |
| May 29, 2025 | ACLX Arcellx, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,784 | $0.00 | $0 | 1,784 | May 30, 2025 |
| Mar 18, 2025 | ACLX Arcellx, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,829 | $0.00 | $0 | 16,829 | Mar 20, 2025 |
| Dec 17, 2024 | OOMA OOMA INC | MOption exercise Common Stock | +35,000 | $6.04 | $211k | 256,756 | Dec 19, 2024 |
| Dec 17, 2024 | OOMA OOMA INC | SOpen-market sale Common Stock | -14,824 | $14.56 | $216k | 241,932 | Dec 19, 2024 |
| Dec 17, 2024 | OOMA OOMA INC | MOption exercise Stock Option (right to buy)derivative | -35,000 | $0.00 | $0 | 0 | Dec 19, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.